Dosage by design-3D printing individualized cabozantinib tablets with immediate release

被引:1
作者
Lenhart, Jonas [1 ]
Lunter, Dominique J. [1 ]
机构
[1] Eberhard Karls Univ Tubingen, Dept Pharmaceut Technol, D-72076 Tubingen, Germany
关键词
3D printing; Hot melt extrusion; Personalized dosage; FabRX; Cabozantinib; Dissolution; Melt rheology; DRUG-RELEASE; 3D; POLYMERS; RHEOLOGY; TOOL; SOLUBILITY; MODEL; SIZE;
D O I
10.1016/j.ejpb.2024.114501
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Production of patient-specific dosage forms is important to improve patient adherence and effectiveness while reducing the prevalence and severity of adverse effects. Due to its possibility of rapid prototyping 3D printing can be used to produce individual dosages while utilizing techniques such as hot melt extrusion to increase the bioavailability of poorly soluble drugs. In this work, Parteck MXP and Kollicoat IR were used as water-soluble polymer bases for formulation development for 3D printing of various dosages incorporating cabozantinib while enabling immediate release. The effect of tablet design and the excipients sorbitol, croscarmellose sodium, and sodium starch glycolate was investigated for this goal. A way to calculate the size of tablets for predetermined dosages is proposed to enable the printing of individual strengths from one formulation. Rheological data were collected to deepen the understanding of the role of melt viscosity in 3D printing and hot melt extrusion processes. The production of immediate-release cabozantinib tablets containing every therapeutically relevant dosage in a single unit produced by two-step 3D printing was realized.
引用
收藏
页数:13
相关论文
共 78 条
  • [1] Rheology as a tool for evaluation of melt processability of innovative dosage forms
    Aho, Johanna
    Boetker, Johan P.
    Baldursdottir, Stefania
    Rantanen, Jukka
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 494 (02) : 623 - 642
  • [2] Gender differences in pharmacological response
    Anderson, Gail D.
    [J]. EPILEPSY IN WOMEN: THE SCIENTIFIC BASIS FOR CLINICAL MANAGEMENT, 2008, 83 : 1 - 10
  • [3] Tablet fragmentation without a disintegrant: A novel design approach for accelerating disintegration and drug release from 3D printed cellulosic tablets
    Arafat, Basel
    Wojsz, Magdalena
    Isreb, Abdullah
    Forbes, Robert T.
    Isreb, Mohammad
    Ahmed, Waqar
    Arafat, Tawfiq
    Alhnan, Mohamed A.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 118 : 191 - 199
  • [4] Basit AW., 2022, Pharm. J, V308, P7959, DOI [DOI 10.1211/PJ.2022.1.135581, 10.1211/PJ.2022.1.135581]
  • [5] Interpretation of regulatory factors for 3D printing at hospitals and medical centers, or at the point of care
    Beitler, Brian G.
    Abraham, Paul F.
    Glennon, Alyssa R.
    Tommasini, Steven M.
    Lattanza, Lisa L.
    Morris, Jonathan M.
    Wiznia, Daniel H.
    [J]. 3D PRINTING IN MEDICINE, 2022, 8 (01)
  • [6] Micro-scale prediction method for API-solubility in polymeric matrices and process model for forming amorphous solid dispersion by hot-melt extrusion
    Bochmann, Esther S.
    Neumann, Dirk
    Gryczke, Andreas
    Wagner, Karl G.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2016, 107 : 40 - 48
  • [7] Modifying release characteristics from 3D printed drug-eluting products
    Boetker, Johan
    Water, Jorrit Jeroen
    Aho, Johanna
    Arnfast, Laerke
    Bohr, Adam
    Rantanen, Jukka
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 90 : 47 - 52
  • [8] Direct Powder Extrusion 3D Printing of Praziquantel to Overcome Neglected Disease Formulation Challenges in Paediatric Populations
    Boniatti, Janine
    Januskaite, Patricija
    Fonseca, Lais B. da
    Vicosa, Alessandra L.
    Amendoeira, Fabio C.
    Tuleu, Catherine
    Basit, Abdul W.
    Goyanes, Alvaro
    Re, Maria-Ines
    [J]. PHARMACEUTICS, 2021, 13 (08)
  • [9] 3D printing using powder melt extrusion
    Boyle, Bret M.
    Xiong, Panupoan T.
    Mensch, Tara E.
    Werder, Timothy J.
    Miyake, Garret M.
    [J]. ADDITIVE MANUFACTURING, 2019, 29
  • [10] Chandrasekar R., 2023, Int. J. Pharmaceut. Sci. Nanotechnol. (IJPSN), V16, P6266, DOI [10.37285/ijpsn.2023.16.1.2, DOI 10.37285/IJPSN.2023.16.1.2]